-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CDK4/6 inhibitors are popular target drugs in the field of tumor therapy and are considered by the industry to have huge market prospects
.
In recent years, in the domestic CDK4/6 inhibitor market, a large number of domestic and foreign pharmaceutical companies have accelerated their deployment in this field.
Foreign pharmaceutical companies such as Eli Lilly and Pfizer, and domestic companies such as Hengrui Medicine and Chia Tai Tianqing
.
On March 6, Eli Lilly announced that its CDK4/6 inhibitor Abeccil (trade name: Weizhe) was launched in China for early breast cancer indications.
This product is also the first domestically approved product for the treatment of early breast cancer.
CDK4/6 inhibitors will bring new treatment options to the majority of breast cancer patients in China
.
It is understood that Eli Lilly Abecili was approved for marketing in March 2021 for the treatment of advanced breast cancer, and the revenue of this product in 2021 has exceeded 1 billion US dollars
.
In addition to Eli Lilly, Pfizer's oral targeted CDK4/6 inhibitor palbociclib entered the Chinese market as early as August 2018, becoming the first CDK4/6 inhibitor to be marketed in China
.
Looking at local pharmaceutical companies, in recent years, a number of domestic pharmaceutical companies are also actively deploying in the field
.
At the end of February this year, the launch of the first Chinese original CDK4/6 inhibitor Dalcil (Aerlikon) independently developed by Hengrui Medicine was held, which means that local companies officially opened the “Dar” case in China
.
It is reported that Hengrui Medicine's dalcili for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer related clinical research on advanced rescue therapy and early adjuvant therapy is advancing in an orderly manner
.
On January 7, Simcere Pharmaceuticals stated that the new drug marketing application for the first indication (small cell lung cancer) submitted in China by tralacilide for injection has been included in the priority review by the State Food and Drug Administration
.
This product, a cyclin-dependent kinase CDK4/6 inhibitor, is an innovative drug jointly developed by Chia Tai Tianqing and G1 Therapeutics, INC.
("G1").
.
Subsequently, on February 24, Simcere announced the safety and efficacy of tralacril for injection in patients with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin combined with etoposide or topotecan.
A randomized, double-blind, placebo-controlled, multicenter Phase III clinical study (study code: TRACES) on pharmacokinetics and pharmacokinetics achieved the primary clinical endpoint
.
The data showed that Tralaciride for injection significantly reduced the duration of severe neutropenia (DSN) in cycle 1
.
Relevant research results will be announced at academic conferences in the future
.
For another example, in the field of CDK4/6 inhibitor generic drugs, there are also a number of pharmaceutical companies with a layout
.
Among them, Qilu Pharma's 4 types of generic drugs, piperacillin capsules, have been approved for marketing in December 2020
.
It is worth mentioning that in the past, the domestic CDK4/6 inhibitor market was mainly occupied by Pfizer's pipericily.
In the medical insurance negotiations in 2019, 2020 and 2021, although piperbacilli took the medical insurance negotiation bus three times, But none of the results were shortlisted
.
However, on January 18, 2021, shortly after the announcement of the results of the 2020 national talks, Pfizer announced a price reduction for pipericily, and the price of the 125ml/bottle product was reduced from 29,799 yuan to 13,667 yuan, a price reduction of about 54%
.
It is generally believed in the industry that the decision to cut the price of palbociclib was mainly due to pressure from competitors.
In addition, Pfizer China's compound patent will expire on January 10, 2023
.
By the end of 2021, the indications of abeccil for advanced breast cancer have been successfully entered into the national medical insurance catalog through negotiation, which is also the first CDK4/6 inhibitor included in medical insurance in China
.
It is foreseeable that with the entry of more pharmaceutical companies, product price reduction will become a trend in the context of increasingly fierce market competition
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In recent years, in the domestic CDK4/6 inhibitor market, a large number of domestic and foreign pharmaceutical companies have accelerated their deployment in this field.
Foreign pharmaceutical companies such as Eli Lilly and Pfizer, and domestic companies such as Hengrui Medicine and Chia Tai Tianqing
.
On March 6, Eli Lilly announced that its CDK4/6 inhibitor Abeccil (trade name: Weizhe) was launched in China for early breast cancer indications.
This product is also the first domestically approved product for the treatment of early breast cancer.
CDK4/6 inhibitors will bring new treatment options to the majority of breast cancer patients in China
.
It is understood that Eli Lilly Abecili was approved for marketing in March 2021 for the treatment of advanced breast cancer, and the revenue of this product in 2021 has exceeded 1 billion US dollars
.
In addition to Eli Lilly, Pfizer's oral targeted CDK4/6 inhibitor palbociclib entered the Chinese market as early as August 2018, becoming the first CDK4/6 inhibitor to be marketed in China
.
Looking at local pharmaceutical companies, in recent years, a number of domestic pharmaceutical companies are also actively deploying in the field
.
At the end of February this year, the launch of the first Chinese original CDK4/6 inhibitor Dalcil (Aerlikon) independently developed by Hengrui Medicine was held, which means that local companies officially opened the “Dar” case in China
.
It is reported that Hengrui Medicine's dalcili for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer related clinical research on advanced rescue therapy and early adjuvant therapy is advancing in an orderly manner
.
On January 7, Simcere Pharmaceuticals stated that the new drug marketing application for the first indication (small cell lung cancer) submitted in China by tralacilide for injection has been included in the priority review by the State Food and Drug Administration
.
This product, a cyclin-dependent kinase CDK4/6 inhibitor, is an innovative drug jointly developed by Chia Tai Tianqing and G1 Therapeutics, INC.
("G1").
.
Subsequently, on February 24, Simcere announced the safety and efficacy of tralacril for injection in patients with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin combined with etoposide or topotecan.
A randomized, double-blind, placebo-controlled, multicenter Phase III clinical study (study code: TRACES) on pharmacokinetics and pharmacokinetics achieved the primary clinical endpoint
.
The data showed that Tralaciride for injection significantly reduced the duration of severe neutropenia (DSN) in cycle 1
.
Relevant research results will be announced at academic conferences in the future
.
For another example, in the field of CDK4/6 inhibitor generic drugs, there are also a number of pharmaceutical companies with a layout
.
Among them, Qilu Pharma's 4 types of generic drugs, piperacillin capsules, have been approved for marketing in December 2020
.
It is worth mentioning that in the past, the domestic CDK4/6 inhibitor market was mainly occupied by Pfizer's pipericily.
In the medical insurance negotiations in 2019, 2020 and 2021, although piperbacilli took the medical insurance negotiation bus three times, But none of the results were shortlisted
.
However, on January 18, 2021, shortly after the announcement of the results of the 2020 national talks, Pfizer announced a price reduction for pipericily, and the price of the 125ml/bottle product was reduced from 29,799 yuan to 13,667 yuan, a price reduction of about 54%
.
It is generally believed in the industry that the decision to cut the price of palbociclib was mainly due to pressure from competitors.
In addition, Pfizer China's compound patent will expire on January 10, 2023
.
By the end of 2021, the indications of abeccil for advanced breast cancer have been successfully entered into the national medical insurance catalog through negotiation, which is also the first CDK4/6 inhibitor included in medical insurance in China
.
It is foreseeable that with the entry of more pharmaceutical companies, product price reduction will become a trend in the context of increasingly fierce market competition
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
